The FDA has approved Bixlenvo, Gilead’s once-daily single-tablet HIV regimen combining bictegravir and lenacapavir — billed as the smallest once-daily single-pill regimen for the disease.
Approved August 27, 2026, Bixlenvo is for virologically suppressed adults — and is notably the first single-tablet option for people on complex regimens who can’t take currently available one-pill treatments. It pairs bictegravir (an integrase inhibitor) with lenacapavir (a capsid inhibitor); treatment starts with a two-day initiation dose of lenacapavir (Sunlenca), after which patients take only Bixlenvo once daily.
The evidence
Approval was based on the Phase 3 ARTISTRY-1 and ARTISTRY-2 studies (presented at CROI earlier this year), in which Bixlenvo maintained virologic suppression at Week 48 comparable to patients’ prior regimens, and was generally well tolerated with no new safety concerns.
Why it matters
Many people living with HIV who are stable on treatment still take multi-pill or complex regimens — because of resistance, drug interactions, or tolerability. A compact, once-daily single tablet that works even for those harder-to-simplify cases can ease the daily burden of therapy and support long-term adherence, the cornerstone of durable viral control.